Stifel Maintains Buy Rating for Nyxoah: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Stifel has reaffirmed its Buy rating on Nyxoah (NASDAQ:NYXH), increasing the price target from $10.00 to $20.00. Despite a recent 3.03% drop in share price to $15.35, the new target suggests a potential 30.29% upside. Nyxoah specializes in developing solutions for sleep disordered breathing conditions, notably with its Genio system for treating Obstructive Sleep Apnea.
March 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel maintains a Buy rating on Nyxoah, raising the price target from $10.00 to $20.00, indicating a significant potential upside from the current price of $15.35.
The reaffirmation of a Buy rating and a substantial increase in the price target by Stifel suggest a strong confidence in Nyxoah's market position and its product, the Genio system, for treating Obstructive Sleep Apnea. Despite a recent drop in share price, the analyst's outlook indicates a belief in the company's potential for significant growth, likely driven by its innovative healthcare solutions.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100